Skip to content

Low-dose GH Supplementation Increases Clinical Pregnancy Rate

Low-dose Growth Hormone Supplementation Increases Clinical Pregnancy Rate in Poor Responders Undergoing in Vitro Fertilisation.

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02359695
Enrollment
64
Registered
2015-02-10
Start date
2013-10-31
Completion date
2017-05-31
Last updated
2017-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Keywords

Poor ovarian response, IVF, Growth hormone

Brief summary

The objective of this study is to assess whether a low dose of GH supplementation (0.5 IU/day) increases clinical pregnancy rates in women with a history of POR who failed to become pregnant in two previous IVF cycles.

Detailed description

The investigators aim to study the impact of a low-dose growth hormone (GH) supplementation in pregnancy rates in poor responders in a prospective, self-controlled study of 64 poor responders to previous IVF cycles who failed to achieve pregnancy and were supplemented with low-doses of GH in a subsequent cycle using the same gonadotropin dose and protocol. Our primary endpoint was the clinical pregnancy rate (CPR), considering secondary endpoints the number of retrieved oocytes, embryos, embryo quality and the proportion of cycles with embryo transfer. Controlled ovarian hyperstimulation will be performed using a GnRH agonist long protocol from day 21-23 of the menstrual cycle at a dose of 1 mg/ day, using the same schedule and dose as in the previous cycle, so that the only difference between them is the GH supplementation. After confirming pituitary inhibition, the dose of GnRH agonist will be decreased to 0.5 mg/day, and COH will begin with gonadotropins at a dose of 300 UI, subsequently adjusting according to clinical response. Human chorionic gonadotropin (hCG) will be administered when follicles reached \> 17 mm in diameter. A dose of 0.5 IU of GH will be administered daily from the first day of the agonist until the day of hCG administration. Oocyte retrieval will be performed 36 hours after hCG administration by ultrasound-guided follicle aspiration.

Interventions

DRUGGrowth Hormone

A dose of 0.5 IU of growth hormone will be administered daily from the first day of the agonist until the day of hCG administration

Sponsors

Centro de Infertilidad y Reproducción Humana
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* Women with a history of POR, defined according to the Bologna criteria * Absence of pregnancy in at least two previous IVF cycles

Exclusion criteria

* Body mass index ≥ 30 kg/m2 * Presence of endocrinopathies * Altered karyotype in one or both partners * History of invasive ovarian surgery * History of chronic, autoimmune or metabolic diseases * Altered meiosis in testicular biopsy or altered sperm-FISH * Drug therapy in the male partner * Participation, within the previous 6 months, in another clinical trial with medication

Design outcomes

Primary

MeasureTime frameDescription
Clinical pregnancy rate7 weeks of gestationPresence of an intrauterine gestational sac with embryonic cardiac activity display, evaluated by ultrasound

Secondary

MeasureTime frameDescription
Retrieved oocytesOn egg retrieval dayTotal number of retrieved oocytes
Number of obtained embryos3 days after egg retrievalTotal number of obtained embryos
Embryo quality3 days after embryo transferTotal number of top quality embryos per cycle
Proportion of cycles with embryo transfer3 days after egg retrievalProportion of cycles reaching embryo transfer per initiated cycle

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026